Table 2

Primary outcome of clinic attendance

Intervention period (0–18 months)Follow-up period (18–30 months)
Intervention group (n = 104)Control group (n = 101)P valueIntervention group (n = 104)Control group (n = 101)P value
Number of scheduled visits0.002*0.846
 021 (20.2%)20 (19.8%)
 11 (1.0%)1 (1.0%)32 (30.8%)34 (33.7%)
 24 (3.9%)6 (5.9%)51 (49.0%)47 (46.5%)
 32 (1.9%)13 (12.9%)
 418 (17.3%)17 (16.8%)
 528 (26.9%)38 (37.6%)
 651 (49.0%)26 (25.7%)
Mean (SD)4.1 (1.1)3.6 (1.2)1.3 (0.8)1.3 (0.8)
Median4.04.01.01.0
Number of scheduled or unscheduled visits0.001*0.905
 01 (1.0%)1 (1.0%)21 (20.2%)20 (19.8%)
 14 (3.9%)6 (5.9%)32 (30.8%)32 (31.7%)
 22 (1.9%)11 (10.9%)45 (43.3%)41 (40.6%)
 316 (15.4%)18 (17.8%)4 (3.9%)8 (7.9%)
 426 (25.0%)37 (36.6%)1 (1.0%)0 (0.0%)
 551 (49.0%)28 (27.7%)0 (0.0%)0 (0.0%)
 64 (3.9%)0 (0.0%)1 (1.0%)0 (0.0%)
Mean (SD)4.2 (1.2)3.7 (1.2)1.4 (1.0)1.4 (0.9)
Median5.04.01.01.0
Attended visit 766 (63.5%)66 (65.4%)0.773
Attended visit 868 (65.4%)62 (61.4%)0.545
  • Data are mean (SD) or n (%) unless otherwise indicated. Analyses were performed using the Mantel-Haenszel test, adjusting for site and local baseline HbA1c (<8.5% [69 mmol/mol] or ≥8.5% [69 mmol/mol]). For any visit or scheduled visit, where the visits are ordinal, the test used for comparing means score differences was equivalent to a Kruskal-Wallis test, adjusting for strata.

  • *P < 0.05.